This week in MathOnco 174

Adaptive therapy predictions, somatic evolution, multi-drug synergy, spheroid structure, and modeling the mechanism

“This week in Mathematical Oncology” — Newsletter
> mathematical-oncology.org

August 12, 2021

From the editor:
> jeffrey.west@moffitt.org


As summer winds down, the pace of publication seems to ramp up. This week’s issue is filled with exciting topics: Adaptive therapy predictions, somatic evolution, multi-drug synergy, spheroid structure, and modeling the mechanism. Enjoy,

- Jeffrey West

1. Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics
   Renee Brady-Nicholls, Jingsong Zhang, Tian Zhang, Andrew Z. Wang, Robert Butler, Robert A. Gatenby, Heiko Enderling

2. Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis
   Jacob G Scott, Geoffrey Sedor, Patrick Ellsworth, Jessica A Scarborough, Kamran A Ahmed, Daniel E Oliver, Steven A Eschrich, Michael W Kattan, Javier F Torres-Roca

3. The somatic molecular evolution of cancer: Mutation, selection, and epistasis
   Krishna Dasari, Jason A. Somarelli, Sudhir Kumar, Jeffrey P. Townsend

4. A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor—Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy
   Chang Gong, Alvaro Ruiz-Martinez, Holly Kimko, Aleksander S. Popel

5. PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma
   Kimiko Koiwai, Raouf El-Cheikh, Hoai-Thu Thai, Claire Brillac, …, Marie-Laure Risse, Helgi van de Velde, Dorothée Semiond, Laurent Nguyen

6. Evolutionary Dynamics of Treatment-Induced Resistance in Cancer Informs Understanding of Rapid Evolution in Natural Systems
   Mariyah Pressley, Monica Salvioli, David B. Lewis, Christina L. Richards, Joel S. Brown, Kateřina Staňková

7. Collapse of Intra-Tumor Cooperation Induced by Engineered Defector Cells
   Marco Archetti

8. MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery
   David J. Wooten, Christian T. Meyer, Alexander L. R. Lubbock, Vito Quaranta, Carlos F. Lopez

1. Quantitative analysis of tumour spheroid structure
   Alexander P Browning, Jesse A Sharp, Ryan J Murphy, Gency Gunasingh, Brodie Lawson, Kevin Burrage, Nikolas K Haass, Matthew J Simpson

1. Do mechanisms matter?
   The Mathematical Oncology Blog
   Fred Adler: “Adaptive therapy depends on three key assumptions: resistance is costly, resistant cells can be suppressed by competition with sensitive cells, and therapy reduces the population of sensitive cells (although Viossat & Noble show that the first of these assumptions is not essential). However, what happens when these assumptions are tested against a wider set of ecological backgrounds? We expanded on the original work by Zhang et al […] to investigate four extensions of a basic competition model: 1) competition with healthy cells, 2) inclusion of resource dynamics, 3) an immune response, and 4) an Allee effect. We tested how a comprehensive set of intermittent and adaptive therapies balance two types of treatment failure (the time when resistant cells exceed some threshold and the time when the total cell population exceeds a different threshold) and two costs: average cell population and total treatment burden.”

The newsletter now has a dedicated homepage (thisweekmathonco.substack.com), which allows us to post cover artwork for each issue. We encourage submissions that coincide with the release of a recent paper from your group.

Caption: We use clinical data of intermittent, adaptive prostate cancer hormone therapy to simulate tumor growth and treatment response dynamics. With that, we can predict possible patient-specific response trajectories to subsequent treatment cycles and recommend treatment adaptations when necessary. Click here to read more.

Created by: Heiko Enderling and Renee Brady-Nicholls.

Visit the mathematical oncology page to view jobs, meetings, and special issues. We will post new additions here, but the full list can found at mathematical-oncology.org.

1. Jobs

• NEW: Senior Quantitative Systems Pharmacologist (Pfizer Oncology, La Jolla, CA) - Open until filled (Contact Blerta Shtylla: Blerta.Shtylla@pfizer.com)

2. Conferences / Meetings

3. Special issues

• Evolutionary Medicine: A Special Issue
  eLife is pleased to present a Special Issue to highlight recent advances in the growing and increasingly interdisciplinary field of evolutionary medicine.

Current subscriber count: ~1k